ATNM logo

Actinium Pharmaceuticals (ATNM) Cash From Financing

Annual CFF

$14.87 M
-$8.24 M-35.65%

December 31, 2023

Summary

Performance

1-Year Change

-35.65%

3-Year Change

-80.48%

5-Year Change

-12.43%

15-Year Change

-20.97%

ATNM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

63.13%
ATNM annual cash flow from financing activities is higher than 63.13% of companies in Healthcare sector

High & Low

All-time High

$76.18 M
ATNM annual cash flow from financing activities is currently -80.48% below its historical high of $76.18 million

3-Year Low

$14.87 M
ATNM annual cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
ATNM previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Apr 25, 2025
ATNM next annual earnings announcement is scheduled for Apr 25, 2025

OtherATNMcash flowmetrics:

Annual CFI

-$153.00 K
ATNM annual cash flow from investing activities is -$153.00 thousand

Annual CFO

-$47.34 M
ATNM annual cash flow from operations is -$47.34 million

Annual FCF

-$47.49 M
ATNM annual free cash flow is -$47.49 million

Annual CAPEX

$153.00 K
ATNM annual capital expenditures is $153.00 thousand

Quarterly CFF

$4.60 M
-$5.35 M-53.77%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+286.07%

3-Year Change

-20.33%

5-Year Change

+1214.86%

ATNM Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

79.46%
ATNM quarterly cash flow from financing activities is higher than 79.46% of companies in Healthcare sector

High & Low

All-time High

$52.03 M
ATNM quarterly cash flow from financing activities is currently -91.16% below its historical high of $52.03 million

3-Year Low

-$22.00 K

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ATNM previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 25, 2025
ATNM next earnings announcement is scheduled for Apr 25, 2025

OtherATNMcash flowmetrics:

Quarterly CFI

$0.00
ATNM quarterly cash flow from investing activities is $0.00

Quarterly CFO

-$11.97 M
ATNM quarterly cash flow from operations is -$11.97 million

Quarterly FCF

-$11.97 M
ATNM quarterly free cash flow is -$11.97 million

Quarterly CAPEX

-
ATNM quarterly capital expenditures value is unknown

TTM CFF

$30.52 M
+$1.74 M+6.05%

September 30, 2024

Summary

Performance

3-Month Change

0%

1-Year Change

+105.22%

3-Year Change

-45.75%

5-Year Change

+78.31%

ATNM TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

69.19%
ATNM TTM cash flow from financing activities is higher than 69.19% of companies in Healthcare sector

High & Low

All-time High

$87.97 M
ATNM TTM cash flow from financing activities is currently -65.31% below its historical high of $87.97 million

3-Year Low

$14.87 M
ATNM TTM cash flow from financing activities is currently +105.22% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
ATNM previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Apr 25, 2025
ATNM next earnings announcement is scheduled for Apr 25, 2025

OtherATNMcash flowmetrics:

TTM CFI

-$11.00 K
ATNM TTM cash flow from investing activities is -$11.00 thousand

TTM CFO

-$34.81 M
ATNM TTM cash flow from operations is -$34.81 million

TTM FCF

-$34.82 M
ATNM TTM free cash flow is -$34.82 million

TTM CAPEX

-
ATNM TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

ATNM Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-35.6%+286.1%+105.2%
3 y3 years-80.5%-20.3%-45.8%
5 y5 years-12.4%+1214.9%+78.3%

ATNM Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-57.8%at low-72.4%>+9999.0%-13.4%+105.2%
5 y5-year-80.5%at low-91.2%+2100.9%-65.3%+105.2%
alltimeall time-80.5%>+9999.0%-91.2%+534.8%-65.3%>+9999.0%

Actinium Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2024
-
$4.60 M(-53.8%)
$30.52 M(+6.1%)
Jun 2024
-
$9.95 M(-32.6%)
$28.77 M(-0.3%)
Mar 2024
-
$14.77 M(+1138.9%)
$28.87 M(+94.1%)
Dec 2023
$14.87 M(-35.7%)
$1.19 M(-58.3%)
$14.87 M(-19.9%)
Sep 2023
-
$2.86 M(-71.5%)
$18.57 M(+7.4%)
Jun 2023
-
$10.05 M(+1204.9%)
$17.29 M(-27.7%)
Mar 2023
-
$770.00 K(-84.3%)
$23.90 M(+3.4%)
Dec 2022
$23.11 M(-34.4%)
$4.89 M(+210.7%)
$23.11 M(+21.5%)
Sep 2022
-
$1.57 M(-90.5%)
$19.02 M(-18.1%)
Jun 2022
-
$16.66 M(<-9900.0%)
$23.22 M(+11.3%)
Mar 2022
-
-$22.00 K(-102.7%)
$20.86 M(-40.8%)
Dec 2021
$35.22 M(-53.8%)
$801.00 K(-86.1%)
$35.22 M(-37.4%)
Sep 2021
-
$5.78 M(-59.6%)
$56.25 M(+12.0%)
Jun 2021
-
$14.30 M(-0.3%)
$50.24 M(-42.9%)
Mar 2021
-
$14.34 M(-34.3%)
$87.97 M(+15.5%)
Dec 2020
$76.18 M(+345.1%)
$21.83 M(-9590.9%)
$76.18 M(+40.3%)
Sep 2020
-
-$230.00 K(-100.4%)
$54.30 M(-1.1%)
Jun 2020
-
$52.03 M(+1947.0%)
$54.88 M(+207.2%)
Mar 2020
-
$2.54 M(-5877.3%)
$17.86 M(+4.4%)
Dec 2019
$17.11 M(+0.8%)
-$44.00 K(-112.6%)
$17.11 M(-15.8%)
Sep 2019
-
$350.00 K(-97.7%)
$20.32 M(+1.7%)
Jun 2019
-
$15.02 M(+737.9%)
$19.98 M(+411.9%)
Mar 2019
-
$1.79 M(-43.4%)
$3.90 M(-77.0%)
Dec 2018
$16.98 M(-9.7%)
$3.17 M(>+9900.0%)
$16.98 M(+22.7%)
Sep 2018
-
$3900.00(-100.4%)
$13.84 M(-51.9%)
Jun 2018
-
-$1.06 M(-107.1%)
$28.80 M(-9.3%)
Mar 2018
-
$14.87 M(>+9900.0%)
$31.77 M(+68.8%)
Dec 2017
$18.81 M(+19.3%)
$27.50 K(-99.8%)
$18.81 M(-32.9%)
Sep 2017
-
$14.96 M(+684.4%)
$28.04 M(+104.4%)
Jun 2017
-
$1.91 M(-0.5%)
$13.72 M(-15.8%)
Mar 2017
-
$1.92 M(-79.3%)
$16.29 M(+3.3%)
Dec 2016
$15.78 M(-58.0%)
$9.25 M(+1337.5%)
$15.78 M(+38.5%)
Sep 2016
-
$643.50 K(-85.6%)
$11.39 M(-12.9%)
Jun 2016
-
$4.48 M(+220.8%)
$13.08 M(-36.3%)
Mar 2016
-
$1.40 M(-71.3%)
$20.53 M(-45.3%)
Dec 2015
$37.53 M
$4.87 M(+108.4%)
$37.53 M(+14.8%)
DateAnnualQuarterlyTTM
Sep 2015
-
$2.34 M(-80.4%)
$32.70 M(+3.1%)
Jun 2015
-
$11.94 M(-35.1%)
$31.71 M(+1.4%)
Mar 2015
-
$18.39 M(>+9900.0%)
$31.26 M(+99.0%)
Dec 2014
$15.71 M(+152.4%)
$39.00 K(-97.1%)
$15.71 M(-15.4%)
Sep 2014
-
$1.34 M(-88.3%)
$18.57 M(+8.0%)
Jun 2014
-
$11.49 M(+305.0%)
$17.19 M(+88.4%)
Mar 2014
-
$2.84 M(-2.0%)
$9.13 M(+46.6%)
Dec 2013
$6.22 M(+21.3%)
$2.90 M(-8823.8%)
$6.22 M(-20.2%)
Sep 2013
-
-$33.20 K(-101.0%)
$7.80 M(-0.4%)
Jun 2013
-
$3.43 M(-5346.4%)
$7.83 M(+77.8%)
Mar 2013
-
-$65.30 K(-101.5%)
$4.40 M(-14.1%)
Dec 2012
$5.13 M(-14.9%)
$4.47 M(>+9900.0%)
$5.13 M(-23.0%)
Sep 2012
-
$0.00(0.0%)
$6.67 M(0.0%)
Jun 2012
-
$0.00(-100.0%)
$6.67 M(-0.2%)
Mar 2012
-
$660.20 K(-89.0%)
$6.68 M(+10.9%)
Dec 2011
$6.03 M(<-9900.0%)
$6.01 M(>+9900.0%)
$6.03 M(>+9900.0%)
Sep 2011
-
$0.00(-100.0%)
$25.10 K(+638.2%)
Jun 2011
-
$15.90 K(+287.8%)
$3400.00(-133.7%)
Mar 2011
-
$4100.00(-19.6%)
-$10.10 K(+4.1%)
Dec 2010
-$9800.00(-152.4%)
$5100.00(-123.5%)
-$9700.00(-17.1%)
Sep 2010
-
-$21.70 K(-1004.2%)
-$11.70 K(-177.0%)
Jun 2010
-
$2400.00(-46.7%)
$15.20 K(+17.8%)
Mar 2010
-
$4500.00(+45.2%)
$12.90 K(-30.6%)
Dec 2009
$18.70 K(+34.5%)
$3100.00(-40.4%)
$18.60 K(+0.5%)
Sep 2009
-
$5200.00(+5100.0%)
$18.50 K(+2.2%)
Jun 2009
-
$100.00(-99.0%)
$18.10 K(-13.8%)
Mar 2009
-
$10.20 K(+240.0%)
$21.00 K(+52.2%)
Dec 2008
$13.90 K(-35.3%)
$3000.00(-37.5%)
$13.80 K(-9.8%)
Sep 2008
-
$4800.00(+60.0%)
$15.30 K(-27.5%)
Jun 2008
-
$3000.00(0.0%)
$21.10 K(+1.0%)
Mar 2008
-
$3000.00(-33.3%)
$20.90 K(-2.3%)
Dec 2007
$21.50 K(+48.3%)
$4500.00(-57.5%)
$21.40 K(+26.6%)
Sep 2007
-
$10.60 K(+278.6%)
$16.90 K(+168.3%)
Jun 2007
-
$2800.00(-20.0%)
$6300.00(+80.0%)
Mar 2007
-
$3500.00
$3500.00
Dec 2006
$14.50 K
-
-

FAQ

  • What is Actinium Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Actinium Pharmaceuticals?
  • What is Actinium Pharmaceuticals annual CFF year-on-year change?
  • What is Actinium Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Actinium Pharmaceuticals?
  • What is Actinium Pharmaceuticals quarterly CFF year-on-year change?
  • What is Actinium Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Actinium Pharmaceuticals?
  • What is Actinium Pharmaceuticals TTM CFF year-on-year change?

What is Actinium Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of ATNM is $14.87 M

What is the all time high annual CFF for Actinium Pharmaceuticals?

Actinium Pharmaceuticals all-time high annual cash flow from financing activities is $76.18 M

What is Actinium Pharmaceuticals annual CFF year-on-year change?

Over the past year, ATNM annual cash flow from financing activities has changed by -$8.24 M (-35.65%)

What is Actinium Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of ATNM is $4.60 M

What is the all time high quarterly CFF for Actinium Pharmaceuticals?

Actinium Pharmaceuticals all-time high quarterly cash flow from financing activities is $52.03 M

What is Actinium Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, ATNM quarterly cash flow from financing activities has changed by +$3.41 M (+286.07%)

What is Actinium Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of ATNM is $30.52 M

What is the all time high TTM CFF for Actinium Pharmaceuticals?

Actinium Pharmaceuticals all-time high TTM cash flow from financing activities is $87.97 M

What is Actinium Pharmaceuticals TTM CFF year-on-year change?

Over the past year, ATNM TTM cash flow from financing activities has changed by +$15.65 M (+105.22%)